NCT06128369终止3 期
A Randomized, Double-masked, Vehicle-controlled Study Evaluating the Efficacy and Safety of OCS-01 Ophthalmic Suspension in the Treatment of Inflammation and Pain Following Cataract Surgery
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 发起方
- Oculis
- 入组人数
- 117
- 试验地点
- 24
- 主要终点
- Absence of Anterior Chamber Cells at Visit 6.
研究概览
简要总结
This was a randomized, double-masked, vehicle-controlled, Phase 3 study evaluating the efficacy and safety of OCS-01 QD compared to vehicle in the treatment of inflammation and pain following cataract surgery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be planning to undergo unilateral cataract extraction via phacoemulsification and posterior chamber intraocular lens (PCIOL) implantation in the study eye.
- •Have a pin-hole visual acuity (VA) without any other correction > 20 letters (approximately 20/400) in the operative eye and > 35 letters (approximately 20/200) in the fellow eye as measured using an Early Treatment for Diabetic Retinopathy Study (ETDRS) chart at Visit 1 (Day -1 to Day -28 [prior to surgery]).
排除标准
- •Have any intraocular inflammation (e.g., white blood cells or flare) present in either eye at the Visit 1 (Day -1 to Day -28 [prior to surgery]) slit-lamp examination.
- •Have a score > 0 on the Ocular Pain Assessment at Visit 1 (Day -1 to Day -28 [prior to surgery]) in the study eye.
研究组 & 干预措施
Vehicle
Placebo Comparator
1 drop of vehicle in the study eye QD for 14 days, beginning 1-day post-surgery in the study eye.
干预措施: Vehicle (Drug)
OCS-01
Experimental
1 drop of OCS-01 (Dexamethasone ophthalmic suspension, 1.5% [15 mg/mL]) in the study eye once daily (QD) for 14 days, beginning 1-day post-surgery in the study eye.
干预措施: OCS-01 (Drug)
结局指标
主要结局
Absence of Anterior Chamber Cells at Visit 6.
时间窗: Day 15.
Absence of Ocular Pain at Visit 4.
时间窗: Day 4.
次要结局
- Absence of Anterior Chamber Cells at Visits 4 and 5.(Days 4 and 8.)
- Absence of Ocular Pain at Visits 3, 5, and 6.(Days 2, 8, and 15.)
- Absence of Flare at Visits 4, 5, and 6.(Days 4, 8, and 15.)
- Absence of Both Anterior Chamber Cells and Flare at Visits 4, 5, and 6.(Days 4, 8, and 15.)
- Use of Rescue Medication on or Prior to Each Visit.(Days 1, 2, 4, 8, 15, and 22.)
- Use of Rescue Medication Overall.(From first dose until Day 22.)
研究者
研究点 (24)
Loading locations...
相似试验
招募中
1 期
NGGT006 Gene Therapy for Homozygous Familial HypercholesterolemiaHomozygous Familial HypercholesterolemiaNCT06125847First Affiliated Hospital Xi'an Jiaotong University21
尚未招募
早期 1 期
iDAP Injection in the Treatment of Parkinson's DiseaseParkinson DiseaseNCT06583291Anhui Provincial Hospital12
已完成
1 期
A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia MajorBeta-Thalassemia MajorNCT06291961CorrectSequence Therapeutics Co., Ltd9
招募中
1 期
A Clinical Research About CD70-targeted CAR-NKT Cells Therapy in Subjects with Advanced Malignant Solid TumorsAdvanced Malignant Solid TumorsNCT06728189Peking University Cancer Hospital & Institute13
进行中（未招募）
2 期
Androgen Deprivation Therapy Combined With Docetaxel for High Risk Prostate CancerNeoadjuvant Therapy \ High Risk Prostate Cancer \ DocetaxelNCT04869371Hongqian Guo75